key: cord-0913016-jcbywbjq authors: Lin, Yi-Jiun; Lin, Meei-Yun; Chuang, Ya-Shan; Liu, Luke Tzu-Chi; Kuo, Tsun-Yung; Chen, Charles; Ganesan, Shyamala; Fattom, Ali; Bitko, Vira; Lien, Chia-En title: Protection of Hamsters Challenged with SARS-CoV-2 after Two Doses of MVC-COV1901 Vaccine Followed by a Single Intranasal Booster with Nanoemulsion Adjuvanted S-2P Vaccine date: 2022-02-26 journal: bioRxiv DOI: 10.1101/2022.02.24.481901 sha: 703e37fc57107d06d7bb4d7e2e046fd8038f9538 doc_id: 913016 cord_uid: jcbywbjq Intramuscular vaccines have greatly reduced hospitalization and death due to severe COVID-19. However, most countries are experiencing a resurgence of infection driven predominantly by the Delta and Omicron variants of SARS-CoV-2. In response, booster dosing of COVID-19 vaccines has been implemented in many countries to address waning immunity and reduced protection against the variants. However, intramuscular boosting fails to elicit mucosal immunity and therefore does not solve the problem of persistent viral carriage and transmission, even in patients protected from severe disease. In this study, two doses of stabilized prefusion SARS-CoV-2 spike (S-2P)-based intramuscular vaccine adjuvanted with Alum/CpG1018, MVC-COV1901, were used as a primary vaccination series, followed by an intranasal booster vaccination with nanoemulsion (NE01)-adjuvanted S-2P vaccine in a hamster model to demonstrate immunogenicity and protection from viral challenge. Here we report that this vaccination regimen resulted not only in the induction of robust immunity and protection against weight loss and lung pathology following challenge with SARS-CoV-2, but also led to increased viral clearance from both upper and lower respiratory tracts. Our findings showed that intramuscular MVC-COV1901 vaccine followed by a booster with intranasal NE01-adjuvanted vaccine promotes protective immunity against both viral infection and disease, suggesting that this immunization protocol may offer a solution in addressing a significant, unmet medical need for both the COVID-19 and future pandemics. Delta and Omicron variants of SARS-CoV-2. In response, booster dosing of COVID-19 vaccines 23 has been implemented in many countries to address waning immunity and reduced protection 24 against the variants. However, intramuscular boosting fails to elicit mucosal immunity and protection from viral challenge. Here we report that this vaccination regimen resulted not only in 31 the induction of robust immunity and protection against weight loss and lung pathology following 32 challenge with SARS-CoV-2, but also led to increased viral clearance from both upper and lower 33 respiratory tracts. Our findings showed that intramuscular MVC-COV1901 vaccine followed by The main mode of SARS-CoV-2 transmission is through exposure to respiratory 63 secretions or respiratory droplets, which are released from an infected person. Importantly, both symptomatic and asymptomatic infections have been confirmed to result in viral shedding [16] [17] [18] [19] . 65 Consequently, the central role of nasal mucosa in both efficient SARS-CoV-2 infection and 66 transmission has important implications for vaccine development. It has been shown that nasally 67 administered vaccines that establish mucosal immunity at the port of viral entry and induce a 68 systemic immune response are of considerable prophylactic value, as they can provide sterilizing The 60% NE01 adjuvant was prepared by high shear homogenization of water, ethanol, 108 cetylpyridinium chloride, non-ionic surfactants, and highly refined soybean oil to form an oil-in-109 water nanoemulsion with a mean particle size of ~400 nm as described previously 32 . The vaccine 110 was prepared by mixing S-2P with NE01 adjuvant for a final concentration of 10 µg of S-2P with 111 20% NE01/dose. Immunization and challenge of hamsters 113 Hamsters were grouped into six groups A-F (n = 8 for Groups A to E, n = 6 for Group F) as shown 114 in Table 1 and immunized with the following regimens: Hamsters were challenged with 1 x 10 4 PFU of SARS-CoV-2 4-5 weeks after intranasal booster 146 administration, as described previously 31 and histopathological examination were performed as described earlier 31 . Quantification of viral titer by cell culture infectious assay (TCID50) 152 The viral titer determination from lung tissue was performed as described previously 31 . In brief, (Figures 4 and 5) . Finally, body weight measurements and lung pathology scores 256 showed significant weight loss and high pathology scores only for the unvaccinated control group 257 (Figures 3 and 6) . We conclude that IN vaccination with our vaccine formulation demonstrated 258 no significant safety concerns. Overall, this data set warrants further investigation of this intranasal 259 vaccine. We are also encouraged that the vaccine generated noticeable benefit as a booster, World Health Organization. WHO Director-General's opening remarks at the mission briefing on COVID-19-323 11 March 2020. World Health Organization A pneumonia outbreak associated with a new 327 coronavirus of probable bat origin COVID-19 Vaccines and Vaccination Mohr 331 NM, Zepeski A. Comparative effectiveness of Moderna United States Safety and Efficacy of the 335 BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of Single-339 Dose Ad26.COV2.S Vaccine against Covid-19 Oxford-AstraZeneca COVID-19 vaccine efficacy CoVariants: SARS-CoV-2 Mutations and Variants of Interest 10. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing: Update on hospitalization and vaccine effectiveness for Omicron VOC-21NOV-01 345 (B.1.1.529) Vaccine over 6 Months Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. medRxiv Aerodynamic analysis of SARS-CoV-2 in two Wuhan 355 hospitals SARS-CoV-2 entry factors are 357 highly expressed in nasal epithelial cells together with innate immune genes Genetics Reveals a Variable Infection Gradient in the Respiratory Tract CpG-adjuvanted stable prefusion SARS-CoV-400 2 spike protein protected hamsters from SARS-CoV-2 challenge Pre-clinical evaluation of 402 a novel nanoemulsion-based hepatitis B mucosal vaccine Detection of 2019 novel coronavirus 404 (2019-nCoV) by real-time RT-PCR Anti-spike IgG causes severe acute lung injury by skewing 406 macrophage responses during acute SARS-CoV infection Pathogenesis of SARS-CoV-2 in Transgenic 408 Mice Expressing Human Angiotensin-Converting Enzyme 2 Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian 411 influenza virus challenge. Vaccine Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against 414 viral challenge in cotton rats. Human vaccines & immunotherapeutics Intranasal immunization of ferrets with commercial trivalent 416 influenza vaccines formulated in a nanoemulsion-based adjuvant. Clinical and Vaccine Immunology Virological assessment of hospitalized patients with COVID-2019 Protection of Hamsters 422 Challenged with SARS-CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Single Dose of Beta Variant Version of MVC-COV1901. bioRxiv The reactogenicity and immunogenicity of a booster dose 425 after the second dose of a protein subunit vaccine MVC-COV1901. medRxiv